2016 Webcasts

The majority of webcasts from the Congress are available on this page. Where there are gaps, we are awaiting final approvals from faculty/study teams; these will be added when available.

Daily news bulletins from HIV Glasgow 2016

News At One - Monday 24 October 2016

News At One
Monday 24 October

News At One Tuesday 25 October 2016

News At One
Tuesday 25 October

 

 

 

 

 

 

News At One Wednesday 26 October 2016

News At One
Wednesday 26 October

News At One Review of PrEP Session by Chloe Orkin and Simon Collins

Review of PrEP Session by Chloe Orkin and Simon Collins

 

 

 

 

 

 

Webcasts from HIV Glasgow 2016

Please click on the below to go straight to the programme entries for the relevant dates:

Sunday 23 October
Monday 24 October
Tuesday 25 October
Wednesday 26 October

Sunday 23 October

Interactive Case Study Session
In collaboration with the University of Liverpool Drug Interactions Website:
www.hiv-druginteractions.org

Welcome and update on DDI websites Webcast
Saye Khoo, University of Liverpool, Liverpool, UK
Long-acting ARVs for PrEP
Ian McGowan, University of Pittsburgh, Pennsylvania, USA
Case: more than just ARVs and chemotherapy Webcast
Presenter:Alessia Dalla Pria, Chelsea and Westminster Hospital, London, UK
Discussant: Fiona Marra, Gartnavel Hospital, Glasgow, UK
Closing remarks Webcast
Saye Khoo

Official Opening and Welcome from Glasgow City Webcast
Andrew Phillips, University College London, UK
Bailie Marie Garrity, Glasgow City Council, Glasgow, UK

Joep Lange and Jacqueline van Tongeren Memorial Lecture
Introduction Webcast
Catherine Hankins, Amsterdam Institute for Global Health and Development, University
of Amsterdam, Amsterdam, The Netherlands
Ending the HIV/AIDS pandemic: follow the science Webcast
Anthony Fauci, National Institute of Allergy and Infectious Diseases (NIAID)/ National
Institute of Health (NIH), Bethesda, USA

Keynote Lectures
Treatment for cancer, HIV and viral hepatitis in Europe using low cost generic drugs: what could be done? Webcast
Andrew Hill, St Stephens AIDS Trust, Chelsea and Westminster Hospital,London, UK
Revolution in prevention in low and middle income settings Webcast
Linda-Gail Bekker, The Desmond Tutu HIV Centre, University of Cape Town,
Cape Town, South Africa, and President, International AIDS Society (IAS)

Back to top

Monday 24 October

Antiretrovirals: Progress and Remaining Challenges
Lock Lecture: Introduction Webcast
David Galloway, President, Royal College of Physicians and Surgeons of Glasgow, Glasgow, UK
Lock Lecture: HIV treatment as prevention, from a research hypothesis to a new global target and beyond Webcast
Julio Montaner, British Columbia Centre for Excellence in HIV/AIDS, and University of British Columbia, Vancouver, Canada
Initiation of ART early in HIV infection: START to Finish Webcast
Jens Lundgren, CHIP and PERSIMUNE, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Transition to adult care Webcast
Pablo Rojo, Paediatric Infectious Diseases, Hospital 12 de Octubre, Complutense University, Madrid, Spain
Persistent disparities in meeting WHO/UNAIDS targets for ART coverage and ART-induced HIV RNA suppression across Europe Webcast
Kamilla Grønborg Laut, Centre for Health and Infectious Disease Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Panel discussion Webcast

Treatment strategies
Simplification to atazanavir/ritonavir + lamivudine versus maintaining atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-infected patients: 96-week data of the ATLAS-M trial Webcast
Roberta Gagliardini, Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
Dual therapy with a boosted protease inhibitor plus lamivudine is an effective maintenance strategy in patients on second-line antiretroviral therapy in Africa: the ANRS 12286/MOBIDIP trial Webcast
Laura Ciaffi, UMI 233, IRD INSERM, Montpellier, France
Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks Webcast
Chloe Orkin, Department of Infection and Immunity, Royal London Hospital, Barts Health NHS Trust, London, UK
Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults
Francois Raffi, Infectious and Tropical Diseases, CHU de Nantes, Nantes, France

Antiretroviral Therapy: Efficacy and Adverse Events – Poster Discussions
Durability and tolerability of first-line combination including two NRTI and RAL or ATV/r or DRV/r in patients enrolled in the ICONA Foundation cohort Webcast
Antonella D’Arminio Monforte, Department of Health Sciences, Clinic of Infectious and Tropical Diseases, University of Milan, Milan, Italy
Efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed-dose combination (FDC) compared with ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA study): subgroup analyses Webcast
Margaret Johnson, Centre for HIV Medicine, Royal Free Hospital, London, UK
Psychiatric adverse events from the DTG ART-Naïve Phase 3 clinical trials Webcast
Romina Quercia, Research and Development, ViiV Healthcare, Brentford, UK (Industry Speaker)
Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system (CNS) toxicity Webcast
Nicole Pagani, St Stephen’s AIDS Trust, Chelsea and Westminster Hospital, London, UK
Tryptophan metabolism and its relationship with central nervous system toxicity in subjects switching from efavirenz to dolutegravir Webcast
Michael Keegan, HIV Research Unit, Clinical Trials Centre, Imperial College London and ViiV Healthcare Ltd, London, UK (Industry Speaker)
High rates of multi-class drug resistance in HIV-1 infected individuals monitored with CD4 cell count in Uganda Webcast
Amrei Von Braun, College of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala, Uganda

Ageing and Cancer – Poster Discussions
Ageing and the evolution of comorbidities among HIV patients in the EuroSIDA cohort Webcast
Sara Lopes, Health Economics and Outcomes Research, Gilead Sciences, London, UK (Industry Speaker)
The extent of B-cell activation and dysfunction preceding lymphoma development Webcast
Alvaro Borges, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark
Future challenges for clinical care of an ageing population infected with HIV: a ‘geriatric HIV’ modelling study Webcast
Davide De Francesco, Department of Infection and Population Health, University College London, London, UK
Quantifying the future clinical burden of an ageing HIV-positive population in Italy: a mathematical modelling study Webcast
Mikaela Smit, Department of Infectious Disease Epidemiology, Imperial College London, London, UK
Health-related costs in chronic HIV infection: a case-control study versus general population using a claims-based approach in Germany Webcast
Eva Wolf, Clinical Research, MUC Research, Munich, Germany
Survival in HIV-1 infected individuals with diagnosis of lymphoma compared to general population: data from ICONA Foundation cohort study Webcast
Antonella Cingolani, Infectious Diseases, Catholic University, Rome, Italy

Challenging Cases in HIV
Interactive case study session in collaboration with the International Antiviral Society-USA (IAS-USA)
Case 1: Antiretroviral Therapy (ART) strategies: choosing an initial regimen Webcast
Roy Gulick, Weill Cornell Medicine, New York, USA
Case 2: Management of HIV infection in the heavily treatment-experienced patient Webcast
Ian Williams, Department of Infection and Population Health, University College London, London, UK
Case 3: Implementation and Issues in pre-exposure prophylaxis (PrEP) Webcast
Jean-Michel Molina, Saint-Louis Hospital and University of Paris, Paris, France

Keeping the patient in the Centre of Quality Care – What matters?
In collaboration with the International AIDS Society (IAS)
Welcome, introduction and setting the scene Webcast
Linda-Gail Bekker, The Desmund Tutu HIV Centre, University of Cape Town, South Africa, and Governing Council, International AIDS Society
Confidentiality matters – innovative HIV testing Webcast
Cheryl Johnson, World Health Organisation (WHO), Geneva, Switzerland
Convenience matters – catalogue STI testing and PrEP Webcast
Patrick Sullivan, Rollins School of Public Health, Emory University, Atlanta, USA
Context matters – one stop medical care from Eastern Europe to downtown London Webcast
Jeff V Lazarus, Centre for Health and Infectious Disease Research (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain
Choice matters – differentiated models of care Webcast
Helen Bygrave, Southern Africa Medical Unit (SAMU), Médecins Sans Frontières (MSF), Cape Town, South Africa
Clients matter – listening to the voices of people living with HIV Webcast
Kevin Osborne, Director of HIV Programmes and Advocacy, International AIDS Society (IAS), Geneva, Switzerland
Panel discussion and closing remarks Webcast
Led by Anton Pozniak, St Stephen’s Centre, Chelsea and Westminster NHS Trust, London, UK, and Governing Council, International AIDS Society

Back to top

Tuesday 25 October

Co-morbidities and HIV Management
Helping the HIV physician through the challenges of co-morbidities Webcast
Edouard Battegay, Center of Competence Multimorbidity, University Hospital Zurich, Zurich, Switzerland
HIV patients today and 10 years ago: do they have the same needs? Results from cross-sectional analysis of ANRS CO3 Aquitaine cohort Webcast
Charles Cazanave, Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
Long-term impact of lipodystrophy on the risk of morbidity and mortality: a 20-year longitudinal cohort study Webcast
Esteban Martinez, Infectious Diseases Unit, Hospital Clinic-Institut d’Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain
Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients Webcast
Michael Sabranski, Infectious Diseases, ICH Study Center Hamburg, Hamburg, Germany
Cognitive function and depression in HIV-positive individuals and matched controls Webcast
Davide De Francesco, Department of Infection and Population Health, University College London, London, UK
Panel Discussion Webcast

Apps and New Technologies in the Management of HIV Infection
In collaboration with the European AIDS Treatment Group (EATG)
Welcome and introduction Webcast
Lisa Power, Potestasis.com, Cardiff, UK and Alain Volny-Anne, Bangkok, Thailand
New approaches and new technologies to improve access to HIV testing Webcast
Teymur Noori, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
How can we start HIV treatment very soon after HIV diagnosis? Can technology help? Webcast
Tarandeep Anand, The Thai Red Cross AIDS and Research Centre, Bangkok, Thailand
Monitoring HIV infection: use of new technologies and new approaches Webcast
Jennifer Whetham, Brighton & Sussex University Hospitals NHS Trust, Brighton, UK
Use of medical apps and privacy issues: should we be worried about confidentiality? Webcast
François Houyez, European Organisation for Rare Diseases (EURORDIS), Paris, France
Panel discussion and close Webcast

Co-infections and Malignancies
HCV therapies: what have we achieved and remaining challenges?
Andri Rauch, Bern University Hospital and University of Bern, Bern, Switzerland
HPV-associated malignancies in HIV Webcast
Deborah Konopnicki, Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium
Screening for malignancies: what is new? Webcast
Jean Philippe Spano, University Institute of Oncology (IUC)/University Pierre and Marie Curie (UPMC)/Pitié-Salpêtrière Hospital, Paris, France
Differences in virological and immunological risk factors for non-Hodgkin lymphoma (NHL) and Hodgkin (HL): the D:A:D study Webcast
Leah Shepherd, Research Department of Infection and Population, University College London, London, UK
Panel discussion Webcast

Critical issues in Eastern and Central Europe including MDR TB and Hepatitis Co-infection
In collaboration with the European AIDS Clinical Society (EACS)
Welcome and introduction Webcast
Manuel Battegay, Department Infectious Diseases & Hospital Epidemiology, University Hospital Basel, University Basel, Switzerland
MDR or XDR TB case study from Eastern Europe Webcast
Cristiana Oprea, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania
Feedback on the highlights of the TB2016 conference in Durban in July 2016
Jan Fehr, University Hospital of Zurich, Zurich, Switzerland
Tackling the HCV epidemic in the EECA region: a physician’s perspective Webcast
Nikoloz Chkhartishvili, Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia
Panel discussion (TB and HCV co-infection) and closing remarks Webcast
Panel members from above joined by Justyna Kowalska, Medical University of Warsaw, Warsaw, Poland and Jürgen Rockstroh, HIV Outpatient Clinic, University of Bonn, Bonn, Germany

Back to top

Wednesday 26 October

PrEP in High Income Settings Session Summary
In collaboration with the British HIV Association (BHIVA)
Update on the evidence for PrEP effectiveness Webcast
Sheena McCormack, Medical Research Council (MRC) Clinical Trials Unit, University College London, London, UK
Brief overview of cost-effectiveness of PrEP Webcast
Valentina Cambiano, University College London, London, UK
Lessons from implementation in France Webcast
Jean-Michel Molina, Saint-Louis Hospital and University of Paris, Paris, France
Utilization of emtricitabine/tenofovir (FTC/TDF) for HIV pre-exposure prophylaxis in the US by gender (2013-1Q2016) Webcast
Keith Rawlings, Medical Affairs, Gilead Sciences, Foster City, CA, USA (Industry Speaker)
InterPrEP: internet-based pre-exposure prophylaxis (PrEP) with generic tenofovir DF/emtricitabine (TDF/FTC) in London – analysis of pharmacokinetics, safety and outcomes Webcast
Nneka Nwokolo, Chelsea and Westminster Hospital, London, UK
PrEP implementation strategies across Europe – an overview Webcast
Teymur Noori, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
Implementation from the community perspective Webcast
Bruno Spire, French National Institute for Medical Research (INSERM); and AIDES, Pantin, France
Panel, audience discussion and closing remarks Webcast

The Way Forward
Immunology of HIV persistence: implications for the development of a cure Webcast
Steve Deeks, University of California, San Francisco, USA
Where next for ARVs? Webcast
Roy Gulick, Weill Cornell Medicine, New York, USA

Renal and Bone – Poster Discussions
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir Webcast
Sophie Jose, Department of Infection and Population Health, University College London, London, UK
Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV co-infected individuals in sub-Saharan Africa: results from the HEPIK cohort Webcast
Giovanni Villa, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK
The relative impact of antiretroviral drugs and baseline immune status on bone quality in HIV-positive subjects: results from the HIV UPBEAT cohort Webcast
Tara McGinty, School of Medicine/ HIV Molecular Research Group, University College Dublin, Dublin, Ireland
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) versus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent Webcast
Frank Post, HIV Research Centre, King’s College Hospital, London, UK

Pharmacokinetics and Drug Interactions – Poster Discussions
Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations in routine care of HIV-infected children with diverse ethnic origin
Sandra Soeria-Atmadja, Division of Paediatrics, Karolinska Institutet, CLINTEC, Stockholm, Sweden
Efavirenz significantly decreases etonogestrel exposure: results of a bidirectional pharmacokinetic evaluation of efavirenz- and nevirapine-based antiretroviral therapy plus etonogestrel contraceptive implants Webcast
Catherine Chappell, Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA, USA
Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch Webcast
Laura Dickinson, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
Low rifampicin and isoniazid concentrations are associated with delayed sputum conversion in HIV-positive patients co-infected with tuberculosis in Uganda
Jan Fehr, University Hospital of Zurich, Zurich, Switzerland
Interactions between HIV and HCV therapies — how common and who wins? Webcast
Adele Torkington, North West ID Unit, North Manchester General Hospital, Manchester, UK

Antiretroviral Strategies and New Drugs
Non-inferiority of dual-therapy (DT) with darunavir/ritonavir (DRV/r) plus 3TC versus triple-therapy (TT) with DRV/r plus TDF/FTC or ABC/3TC for maintenance of viral suppression: 48-week results of the DUAL-GESIDA 8014 trial Webcast
José Arribas, HIV Unit, University Hospital La Paz, IdiPAZ, Madrid, Spain
French national survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS-AC11 virology network) Webcast
Anne-Genevieve Marcelin, Department of Virology, Pitie-Salpetriere Hospital, Paris, France
Switching from cART to dolutegravir (DTG) maintenance monotherapy in
virologically suppressed HIV-1 infected adults: a randomized multicenter, non-inferiority clinical trial (DOMONO)
Webcast
Bart Rijnders, Internal Medicine, Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands
Subgroup analyses from ONCEMRK, a phase 3 study of raltegravir (RAL) 1200 mg once daily versus RAL 400 mg twice daily, in combination with tenofovir/emtricitabine, in treatment-naïve HIV-1-infected subjects Webcast
Pedro Cahn, Fundacion Huesped, Juan A Fernandez Hospital, Buenos Aires, Argentina
HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 96 subgroup analysis and HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral- experienced subjects: week 96 safety analysis Webcast
Cyril Llamoso, Research and Development, ViiV Healthcare, Wallingford, CT, USA (Industry Speaker)
Efficacy and safety of long-acting HIV fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim 48-week results from the randomized, controlled, phase 3, non-inferiority TALENT study Webcast
Dong Xie, Research and Development, Frontier Biotechnologies Co, Nanjing, China (Industry Speaker)

Congress Closing Remarks Webcast
Giulio Corbelli, European AIDS Treatment Group (EATG), Brussels, Belgium, and Bologna, Italy
Andrew Phillips, University College London, London, UK

Back to top